FDA Approves Oral Therapy for Myelodysplastic Syndromes, CMML FDA Approves Oral Therapy for Myelodysplastic Syndromes, CMML
The Food and Drug Administration has approved Inqovi (decitabine and cedazuridine tablets, Astex Pharmaceuticals) to treat adults with myelodysplastic syndromes or chronic myelomonocytic leukemia (CMML).FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 9, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Oral Treatment for Myelodysplastic Syndrome
WEDNESDAY, July 8, 2020 -- The U.S. Food and Drug Administration has approved Inqovi (decitabine and cedazuridine) tablets, an oral outpatient treatment option for patients with myelodysplastic syndromes and chronic myelomonocytic leukemia, the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 8, 2020 Category: General Medicine Source Type: news
FDA Approves Inqovi (decitabine and cedazuridine) for Myelodysplastic Syndromes (MDS) including Chronic Myelomonocytic Leukemia (CMML)
Pleasanton, CA, Princeton, NJ, and Tokyo, Japan, July 7, 2020. Astex Pharmaceuticals, Inc.; Taiho Oncology, Inc.; and Otsuka Pharmaceutical Co., Ltd. today announce that the U.S. Food and Drug Administration (FDA) and Health Canada have approved... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 7, 2020 Category: Drugs & Pharmacology Source Type: news
Blood cell mutations linked to leukemias are inevitable as we age
(RIKEN) A new study by researchers at the RIKEN Center for Integrative Medical Science in Japan reports differences in blood cell mutations between Japanese and European populations. The study found that these pre-clinical mutations were strongly associated with different types of cancers and can explain why Europeans have higher rates of chronic lymphocytic leukemia, while Japanese have higher rates of T-cell leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2020 Category: Cancer & Oncology Source Type: news
Three-Drug Combo Promising Against High-Risk CLL Three-Drug Combo Promising Against High-Risk CLL
The combination of obinutuzumab, ibrutinib, and venetoclax was associated with a high complete response rate in patients with high-risk chronic lymphocytic leukemia, a phase 2 trial finds.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 15, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Alert Source Type: news
Generic Imatinib Cuts Costs Without Affecting CML Outcomes Generic Imatinib Cuts Costs Without Affecting CML Outcomes
Clinicians and their chronic myeloid leukaemia patients looking to switch to generic imatinib will see no change in outcomes or safety, while markedly reducing healthcare costs, say UK researchers.Medscape News UK (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 5, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Rapid Cognitive Decline in a Patient With CLL Rapid Cognitive Decline in a Patient With CLL
This 68-year-old patient being treated with ofatumumab for chronic lymphocytic leukemia presented with progressive cognitive decline and neurological dysfunction. What was the cause?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 5, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
FDA Grants Orphan Drug Designation to HQP1351 for Chronic Myeloid Leukemia
The FDA granted orphan drug designation to Ascentage Pharma ’s HQP1351 for the treatment of chronic myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - May 5, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
E1912 trial leads to FDA approval of ibrutinib-rituximab combo for untreated CLL
(ECOG-ACRIN Cancer Research Group) Patients aged 70 or younger with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma have a new treatment option -- a combination of the targeted agent ibrutinib with the immunologic agent rituximab. The FDA has approved the combination based on data from E1912, a phase 3 trial that showed this combination provides better leukemia control, prolongs life, and has fewer side effects compared to standard care. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 29, 2020 Category: Cancer & Oncology Source Type: news
FDA Approves Ibrutinib Plus Rituximab Combo for CLL FDA Approves Ibrutinib Plus Rituximab Combo for CLL
This combination of targeted agents showed better progression-free survival than a standard chemoimmunotherapy regimen in patients with newly diagnosed chronic lymphocytic leukemia.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
HORSHAM, Pa., April 21, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are new to therapy. The approval is based on positive results from the landmark Phase 3 E1912 study that was designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute, part of the National Institutes of Health. Today’s milestone mar...
Source: Johnson and Johnson - April 22, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves Ibrutinib Combined with Rituximab for Patients with CLL/SLL
The FDA approved ibrutinib in combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - April 22, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
FDA Approves Imbruvica (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
NORTH CHICAGO, Ill., April 21, 2020– AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the use of Imbruvica® (ibrutinib) in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 21, 2020 Category: Drugs & Pharmacology Source Type: news
Finding leukemia's weakness using genome-wide CRISPR technology
(University of California - San Diego) Researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 20, 2020 Category: Cancer & Oncology Source Type: news
Prognostic Score Predicts Time to First Treatment in Leukemia
WEDNESDAY, April 15, 2020 -- An international prognostic score (IPS-E) can predict time to first treatment (TTFT) for chronic lymphocytic leukemia (CLL) patients with early, asymptomatic disease, according to a study published online April 8 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 15, 2020 Category: Pharmaceuticals Source Type: news
